|
| Place Your Bets
| | September 1, 2008 | The industry is a-changing. Here are eight seminal events that describe how. |
| | 2007 in M&A: 44 deals, $79 billion
| | April 1, 2008 | | The year in pharma and biotech finance. Stock prices stabilized. Pharma M&A kept building. And the mid-cap biotechs finally got a little love. |
| | Big Deals
| | February 1, 2008 | | Many say licensing is the new R&D. We've rounded up the unions to watch from the third quarter of 2007. |
| | M&A: Panning for Gold
| | September 1, 2007 | | here's a solid case to be made for choosing A. The market for deals has been robust through the first half of 2007. A Cowen research report counted 10 public deals done by July 2007, compared with 14 for all of 2006. Another data source, Irving Levin Associates, cites 455 public and private healthcare deals in the first six months of 2007, a 12 percent decrease from the same period last year—but an 18 percent rise in deal value. |
| | Actavis Going Private?
| |
July 3, 2007 | | The month in deals: Merck KGaA's generics unit goes to Mylan; Genzyme acquires its partner in a key oncology drug; and Amgen makes significant acquisitions in kidney disease and diabetes/inflammatory diseases |
|
|
| 
